Eczema & Dupixent
research study
research study
Researchers at Stanford University are investigating the effects of Dupixent in the treatment of atopic dermatitis. Volunteers aged 18 to 65 who are treating their atopic eczema with Dupixent are invited to join.
Eczema & Dupixent
research study
research study
Researchers at Stanford University are investigating the effects of Dupixent in the treatment of atopic dermatitis. Volunteers aged 18 to 65 who are treating their atopic eczema with Dupixent are invited to join.
Study conducted at Redwood City, CA
Compensation Offered
Treating with dupixent
18-65 years old
Quick Overview
Diagnosed with Atopic Dermatitis
Study Background Our researchers want to investigate causes of an adverse reaction to Dupixent in people being treated for eczema. In rare occasions, individuals with atopic eczema who are treated with Dupixent may develop a new skin eruption on their face and/or neck. This study aims to find potential causes of this reaction. If you are using Dupixent to treat your eczema and you have noticed a new rash or worsening dermatitis on your face and/or neck, you may be eligible for the study group. If you are using Dupixent to treat your eczema and you have been responding well to treatment, without new rash or dermatitis, you may be eligible for the control group. Participating in this research study may help researchers develop better treatment strategies for eczema. Join our compensated study today! |
Additional Information
The purpose of this research is to investigate potential causes of new head & neck eruptions in people treating atopic dermatitis with dupilumab (Dupixent).
You may qualify for this study if you meet the following criteria.
Key Criteria:
Key Criteria:
- 18-65 years old
- Using dupilumab (Dupixent) to treat atopic dermatitis
- No known or suspected immunosuppression
- No active malignancies or hematologic disorders (including lymphopenia)
- No known infection, such as HIV or opportunistic infections (tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis)
- No use of phototherapy or tanning in the past 4 weeks
- No other medication by mouth or injection is currently being used to treat atopic dermatitis
- Female patients must not be pregnant or breastfeeding
Your active participation in the study will last about one week, starting with one screening visit (in-person or virtual), followed by one in-person visit at Stanford Dermatology (Redwood City), and two follow-up visits within one week.
During the study, researchers investigate the presence of contact allergy to common allergens by patch testing and also testing for photosensitivity. Other data such as skin surface lipids, microbiome, and inflammatory markers will be studied by noninvasive sampling of skin surface. A one-time blood draw is required. An optional skin biopsy may be included if you choose to.
During the study, researchers investigate the presence of contact allergy to common allergens by patch testing and also testing for photosensitivity. Other data such as skin surface lipids, microbiome, and inflammatory markers will be studied by noninvasive sampling of skin surface. A one-time blood draw is required. An optional skin biopsy may be included if you choose to.
Participants may qualify for compensation up to $450.
There is no cost to you for participating in this study, other than basic expenses like transportation and the personal time it will take to come to all of the study visits.